Ann: Investor Presentation, page-76

PS.: just to spin it on the topic: was it Matt earlier this year referring to Viralytics and to 'assets that can be transacted' without realizing that some may get a clue on BOT's outlook out from it?

Mr Callahan discusses developments and deals in the sector and highlights Australian stocks to watch including biotechnology companies Viralytics Limited (ASX:VLA) (developing oncolytic immunotherapy treatments for a range of cancers in Australia) and Oncosil Medical (ASX:OSL) (medical device company focused on interventional oncology in the pancreas).

Lelde Smits: Hello, I’m Lelde Smits for The Capital Network and joining me from Botanix Pharmaceuticals is it’s founder and executive director, Matthew Callahan. Matthew, welcome.

Matthew Callahan: Thank you.

Lelde Smits: Now you are an expert in the life sciences industry. When it comes to Australia, what are the trends that you are really noticing at the moment?

Matthew Callahan: So I think it is a really exciting time in biotech in Australia at the moment. Not only is there a lot of capital being invested in the industry here but we are starting to see some significant exits of ASX listed companies being acquired by international companies and Viralytics’ recent $500 million exit is a great example of that.

Lelde Smits: What other deals have perhaps been on your radar that you think are worthy of investor attention?

Matthew Callahan: So there’s a number of great Australian companies that are developing fantastic technology and rapidly developing products through the clinic. Oncosil comes to mind, is a very well supported company in this market but there’s are a number of other companies that are beginning to move beyond the early stage that Australian companies are generally known for based on great science through to development stage assets that can be transacted.

[...continue...]

https://www.thecapitalnetwork.com.a...pportunities-For-ASX-Stocks-In-Biotech-Sector